dacarbazine

Summary

Summary: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

Top Publications

  1. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
  2. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
  3. ncbi Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:459-66. 2009
  4. ncbi Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Caroline Robert
    Institute Gustave, Roussy, Villejuif, France
    N Engl J Med 364:2517-26. 2011
  5. pmc PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells
    Anne Marie Bleau
    Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell Stem Cell 4:226-35. 2009
  6. ncbi Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    Anastasia Murat
    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Oncol 26:3015-24. 2008
  7. ncbi Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    M R Middleton
    Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 18:158-66. 2000
  8. ncbi MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda Unità Sanitaria Locale of Bologna, Bologna, Italy
    J Clin Oncol 26:2192-7. 2008
  9. ncbi Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine
    W P Roos
    Department of Toxicology, University of Mainz, Mainz, Germany
    Oncogene 26:186-97. 2007
  10. ncbi Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics of the Neurosurgery Departments of the University Hospitals, Lausanne, Switzerland
    Clin Cancer Res 10:1871-4. 2004

Detail Information

Publications372 found, 100 shown here

  1. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
    ....
  2. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
    ..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety...
  3. ncbi Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:459-66. 2009
    ..We report the final results with a median follow-up of more than 5 years...
  4. ncbi Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Caroline Robert
    Institute Gustave, Roussy, Villejuif, France
    N Engl J Med 364:2517-26. 2011
    ..We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma.
  5. pmc PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells
    Anne Marie Bleau
    Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell Stem Cell 4:226-35. 2009
    ..This Akt-induced ABCG2 activation results from its transport to the plasma membrane. Temozolomide, the standard treatment of gliomas, although not an ABCG2 substrate, increases the SP in glioma cells, especially in cells missing PTEN...
  6. ncbi Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    Anastasia Murat
    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Oncol 26:3015-24. 2008
    ..Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide...
  7. ncbi Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    M R Middleton
    Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 18:158-66. 2000
    To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall survival, progression-free survival (PFS), objective response, and safety, and to assess health-related quality of ..
  8. ncbi MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda Unità Sanitaria Locale of Bologna, Bologna, Italy
    J Clin Oncol 26:2192-7. 2008
    ..The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression...
  9. ncbi Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine
    W P Roos
    Department of Toxicology, University of Mainz, Mainz, Germany
    Oncogene 26:186-97. 2007
    ..Overall, the data demonstrate that cell death induced by TMZ in gliomas is due to apoptosis and that determinants of sensitivity of gliomas to TMZ are MGMT, p53, proliferation rate and DSB repair...
  10. ncbi Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics of the Neurosurgery Departments of the University Hospitals, Lausanne, Switzerland
    Clin Cancer Res 10:1871-4. 2004
    ..Expression of this excision repair enzyme has been associated with resistance to alkylating chemotherapy...
  11. ncbi The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas
    Peter Pyrko
    Department of Pathology, and University of Southern California Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Cancer Res 67:9809-16. 2007
    ....
  12. ncbi Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
    T Kanzawa
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cell Death Differ 11:448-57. 2004
    ..Application of an autophagy inhibitor that works after the association of LC3 with autophagosome membrane, such as bafilomycin A1, is expected to enhance the cytotoxicity of TMZ for malignant gliomas...
  13. ncbi Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    David J Straus
    Memorial Sloan Kettering Cancer Center, SR 441B Box 406, 1275 York Ave, New York, NY 10021, USA
    Blood 104:3483-9. 2004
    ..and IIIA without bulk disease were prospectively randomized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by radiation therapy (RT) (3600 cGy: involved field for 11 patients, ..
  14. pmc Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
    J Dunn
    Department of Surgery and Oncology, School of Cancer Studies, University of Liverpool, Liverpool, UK
    Br J Cancer 101:124-31. 2009
    ..In this study, we investigated MGMT promoter methylation in glioblastomas treated with temozolomide and radiotherapy in a single UK treatment centre...
  15. pmc Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 16:2443-9. 2010
    ..Results of these phase II studies are typically compared with the phase III European Organization for Research and Treatment of Cancer (EORTC) survival data that resulted in RT + TMZ becoming standard therapy...
  16. ncbi Temozolomide preferentially depletes cancer stem cells in glioblastoma
    Dagmar Beier
    Department of Neurology, University of Regensburg, Medical School, Regensburg, Germany
    Cancer Res 68:5706-15. 2008
    ..Accordingly, our data strongly suggest that optimized temozolomide-based chemotherapeutic protocols might substantially improve the elimination of GBM stem cells and consequently prolong the survival of patients...
  17. pmc Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
    Albert Lai
    David Geffen School of Medicine at UCLA, Reed Neurological Research Center, Los Angeles, CA 90095, USA
    J Clin Oncol 29:142-8. 2011
    ..The objectives were to determine the efficacy of this treatment combination and the associated toxicity...
  18. ncbi Temozolomide in malignant gliomas: current use and future targets
    J Lee Villano
    Section of Hematology Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Cancer Chemother Pharmacol 64:647-55. 2009
    ..We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance...
  19. ncbi A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
    Evan M Hersh
    Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
    Invest New Drugs 29:489-98. 2011
    ..We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma.
  20. ncbi Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 78:1147-55. 2010
    ..To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation...
  21. ncbi A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
    Chris Hunter
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Cancer Res 66:3987-91. 2006
    ..These observations highlight the potential of large scale sequencing for revealing and elucidating mutagenic processes operative in individual human cancers...
  22. pmc Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model
    Tai Gyu Kim
    Department of Neurosurgery, Kangnam St Mary s Hospital, The Catholic University of Korea, Banpo dong 505, Seochogu, Seoul 137 701, South Korea
    Clin Vaccine Immunol 17:143-53. 2010
    ..Therefore, CRT exposure, regulatory T cells, and cross-priming by TMZ chemotherapy may be immunological factors related to the enhancement of the antitumor effects of chemoimmunotherapy in an experimental brain tumor model...
  23. pmc Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
    ..The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response...
  24. ncbi O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
    Mirjam Hermisson
    Laboratory of Molecular Neuro Oncology, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Tubingen, Germany
    J Neurochem 96:766-76. 2006
    ..Collectively, these results suggest that the determination of MGMT expression and p53 status will help to identify glioma patients who will or will not respond to TMZ...
  25. ncbi Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy
    Chien Ju Lin
    Department of Biochemistry, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
    Free Radic Biol Med 52:377-91. 2012
    ..Taken together, our data indicate that TMZ-induced ROS/ERK-mediated autophagy protected glioma cells from apoptosis, and the combination of resveratrol with TMZ could improve the efficacy of chemotherapy for brain tumors...
  26. pmc Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
    Duane A Mitchell
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
    Blood 118:3003-12. 2011
    ....
  27. ncbi Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines
    Stephanie E Combs
    Department of Radiation Oncology, University of Heidelberg
    Int J Radiat Biol 85:126-37. 2009
    ..To investigate the cytotoxic effect of high linear-energy transfer (LET) carbon irradiation on glioblastoma cells lines in combination with temozolomide (TMZ)...
  28. pmc Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
    K A van Nifterik
    Department of Radiation Oncology, VU University Medical Center, P O Box 7057, Amsterdam 1007 MB, The Netherlands
    Br J Cancer 103:29-35. 2010
    ....
  29. ncbi Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
    Dieta Brandsma
    Department of Neuro Oncology, Daniel den Hoed Cancer Centre, Erasmus Medical Centre, Rotterdam, Netherlands
    Lancet Oncol 9:453-61. 2008
    ..Further research is needed to establish reliable imaging parameters that distinguish between true tumour progression and pseudoprogression or treatment-related necrosis...
  30. ncbi Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    ..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors...
  31. ncbi Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital, Bologna, Italy
    J Clin Oncol 27:1275-9. 2009
    ....
  32. ncbi The prognostic role of Beclin 1 protein expression in high-grade gliomas
    Luigi Pirtoli
    Department of Human Pathology and Oncology, Section of Radiological Sciences, University of Siena, Italy
    Autophagy 5:930-6. 2009
    ..037). Furthermore, among patients showing a MGMT methylated gene, survival was significantly higher in cases with a higher BPCE score. BPCE score might be added to pathological evaluation of HGG for prognostic purposes...
  33. ncbi Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
    This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.
  34. ncbi Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience
    Silvia Scoccianti
    Department of Radiotherapy, AOU Careggi, University of Florence, Florence, Italy
    Anticancer Drugs 19:613-20. 2008
    ..Fotemustine has shown therapeutic efficacy as single-drug second-line chemotherapy in treatment of TMZ pretreated patients...
  35. pmc Volumetric and MGMT parameters in glioblastoma patients: survival analysis
    Georgios Iliadis
    Department of Radiation Oncology, Papageorgiou Hospital, Thessaloniki, Greece
    BMC Cancer 12:3. 2012
    ..In addition, MGMT (O6-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development...
  36. ncbi Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel
    P Giussani
    Department of Medical Chemistry, Biochemistry and Biotechnology, LITA Segrate, University of Milan, Milan, Italy
    Cancer Invest 30:27-37. 2012
    ..These findings suggest that GCS protects glioblastoma cells against autophagic and apoptotic death, and contributes to cell survival under chemotherapy...
  37. pmc Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma
    Andrea Schäfer
    Division of Neuropathology, Institute of Pathology, Technische Universitat Munchen, Munchen, Germany
    Neuro Oncol 14:1452-64. 2012
    ..0001). ALDH1A1 is a new mediator for resistance of GBM to temozolomide and a reliable predictor of clinical outcome and may serve as a potential target to improve treatment of human GBM...
  38. pmc Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma
    Christina I Tsien
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 18:273-9. 2012
    ....
  39. ncbi Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma
    Michael Brada
    The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 28:4601-8. 2010
    ..No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG...
  40. pmc Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, Ospedale Bellaria Maggiore, Bologna, Italy
    Cancer Chemother Pharmacol 64:769-75. 2009
    ..Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide...
  41. ncbi Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells
    Mahmud Uzzaman
    Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Neurosurg 106:646-51. 2007
    ..The aim of this study was to assess whether TRAIL can be used as an adjuvant to temozolomide (TMZ) for apoptosis induction in malignant glioma cell lines...
  42. pmc O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
    Simone Kreth
    Department of Anaesthesiology, Ludwig Maximilians University, Munich, Germany
    PLoS ONE 6:e17156. 2011
    ....
  43. pmc The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation
    Jana Portnow
    Department of Medical Oncology and Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA
    Clin Cancer Res 15:7092-8. 2009
    ..The goal of this pilot study was to determine the feasibility of using ICMD to examine the neuropharmacokinetics of temozolomide in brain interstitium following oral administration...
  44. pmc Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma
    Arne Christians
    Clinical Cooperation Unit Neuropathology, German Cancer Research Center, DKFZ, Heidelberg, Germany
    PLoS ONE 7:e33449. 2012
    ....
  45. pmc Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    Paul D Brown
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 26:5603-9. 2008
    ..Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial...
  46. ncbi Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects
    Bart Neyns
    Department of Medical Oncology, Oncology Center, UZ Brussel, Brussels, Belgium
    Cancer 116:2868-77. 2010
    ..Further studies exploring the clinical implications of lymphodepletion are warranted...
  47. ncbi The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action
    Roberto Bei
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome 00133, Italy
    Recent Pat Anticancer Drug Discov 5:172-87. 2010
    ..TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide...
  48. ncbi Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
    Andreas Engert
    First Department of Internal Medicine, Coordination Center for Clinical Trials, and Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 25:3495-502. 2007
    ..whether combined-modality treatment (CMT) with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT) is superior to EF-RT alone in patients with early ..
  49. pmc MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance
    Stephen Yip
    Pathology Service, Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4622-9. 2009
    ..This study aimed to clarify the timing and role of MSH6 mutations in mediating glioblastoma temozolomide resistance...
  50. pmc Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
    Daniel P Cahill
    Molecular Pathology Unit, Neurosurgical Service, Brain Tumor Center, and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 13:2038-45. 2007
    ..However, the extent of involvement of MSH6 in glioblastoma is unknown. We sought to determine the overall frequency and clinical relevance of MSH6 alterations in glioblastomas...
  51. ncbi Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
    David B Duggan
    Department of Medicine, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    J Clin Oncol 21:607-14. 2003
    In a series of trials, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV) have been identified as effective ..
  52. ncbi Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide
    Takao Kanzawa
    Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York, USA
    J Neurosurg 99:1047-52. 2003
    ..In this study the authors investigated the ability of O6-benzylguanine (BG), an AGT inhibitor, to sensitize a glioblastoma cell line resistant to TMZ...
  53. pmc Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
    Camilo E Fadul
    Section of Hematology Oncology Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    J Immunother 34:382-9. 2011
    ..Our data suggest that DC vaccination in combination with radiation and chemotherapy in patients with GBM is feasible, safe, and may induce tumor-specific immune responses...
  54. ncbi Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
    Giuseppe Minniti
    Department of Radiation Oncology, Sant Andrea Hospital, University La Sapienza, Via di Grottarossa 1035, 00189, Rome, Italy
    J Neurooncol 102:311-6. 2011
    ..004 and P = 0.005, respectively). The results of the present study suggest that MGMT methylation status might be an important prognostic factor associated with better OS and PFS in elderly patients with GBM treated with RT and TMZ...
  55. ncbi p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells
    Y Hirose
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 94143-0875, USA
    Cancer Res 61:1957-63. 2001
    ..Therefore, the integrity of the G2-M cell cycle checkpoint may be important in the cytotoxicity of TMZ in glioma cells...
  56. ncbi Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma
    Michael D Blough
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    J Neurooncol 102:1-7. 2011
    ..P53 status may influence response to TMZ in differentiated cells in a GBM with a negligible affect on its initiating cells...
  57. ncbi Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells
    Y Hirose
    Brain Tumor Research Center, Department of Neurological Surgery, University of California-San Francisco, 2340 Sutter Street, San Francisco, CA 94143-0875, USA
    Cancer Res 61:5843-9. 2001
    ..Furthermore, inhibition of the cytoprotective G(2) arrest pathway sensitizes cells to TMZ-induced cytotoxicity and may represent a novel, mechanism-based means of increasing TMZ efficacy in both p53 wild-type and p53 mutant glioma cells...
  58. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  59. ncbi Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence
    Yuchi Hirose
    Department of Neurological Surgery and The Brain Tumor Research Center, University of California at San Francisco, San Francisco, California, USA
    Cancer Res 65:4861-9. 2005
    ..The Akt pathway therefore represents a new target for the sensitization of gliomas to chemotherapeutic methylating agents such as temozolomide...
  60. pmc Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression
    Benjamin Le Calve
    Laboratoire de Toxicologie, Institut de Pharmacie, Universite Libre de Bruxelles, Brussels, Belgium
    Neoplasia 12:727-39. 2010
    ..Selective targeting of GLUT-3 in GBM and/or AKR1C proteins (by means of jasmonates, for example) could thus delay the acquisition of resistance to TMZ of astroglioma cells in the context of prolonged treatment with this drug...
  61. pmc Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neuro Oncol 13:324-33. 2011
    ..EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity...
  62. pmc Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition
    Wen bin Zhang
    Department of Physiology, China Pharmaceutical University, Nanjing 210009, China
    J Biol Chem 285:40461-71. 2010
    ..Our study suggests that activation of AMPK by TMZ contributes to glioblastoma cell apoptosis, probably by promoting p53 activation and inhibiting mTORC1 signaling...
  63. pmc Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain
    Claudia R Oliva
    Department of Surgery, Division of Neurosurgery, University of Alabama at Birmingham, Alabama 35294 0006, USA
    J Biol Chem 285:39759-67. 2010
    ..Thus, abrogation of this adaptive response may reverse chemoresistance and restore sensitivity to TMZ, providing a strategy for improved therapeutic outcomes in GBM patients...
  64. pmc Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
    A A Brandes
    Department of Medical Oncology, Bellaria Hospital, 40139 Bologna, Italy
    Br J Cancer 95:1155-60. 2006
    ..The prolonged temozolomide schedule considered in the present study is followed by a high PFS-6 rate; toxicity is acceptable. Further randomised trials should therefore be conducted to confirm the efficacy of this regimen...
  65. ncbi Management of aggressive pituitary adenomas: current treatment strategies
    Michael Buchfelder
    Department of Neurosurgery, University of Erlangen Nurnberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Pituitary 12:256-60. 2009
    ..A combination of these therapies will be required for aggressive pituitary adenomas and careful follow-up is essential...
  66. ncbi Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
    M C Y de Wit
    Department of Neuro Oncology Neurology, Daniel den Hoed Cancer Center Erasmus Medical Center, Rotterdam, The Netherlands
    Neurology 63:535-7. 2004
    ..The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma...
  67. ncbi Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
    Caroline Robert
    Institute Gustave Roussy, Paris, France
    Lancet Oncol 14:733-40. 2013
    ..This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone.
  68. pmc Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities
    Arabinda Das
    Department of Neurology, Medical University of South Carolina, Charleston, USA
    Mol Cancer 3:36. 2004
    ..Temozolomide (TMZ), an alkylating agent, has recently been introduced in clinical trials for treating glioblastoma. Here, we evaluated the modulatory effect of DXM on TMZ induced apoptosis in human glioblastoma U87MG cells...
  69. ncbi Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 115:3512-8. 2009
    ....
  70. pmc Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
    Doo Sik Kong
    Department of Neurosurgery, Samsung Medical Center, Seoul, Korea
    Neuro Oncol 12:289-96. 2010
    ..Metronomic treatment of TMZ is an effective treatment for recurrent GBM that is even refractory to conventional treatment of TMZ and has acceptable toxicity...
  71. ncbi High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma
    H Kim
    Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA
    J Pharm Biomed Anal 24:461-8. 2001
    ..Moreover, temozolomide was stable in acidified human plasma after being subjected to three freeze thaw cycles. The assay was shown to be specific, accurate, precise, and reliable for use in pharmacokinetic studies...
  72. ncbi Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy
    Justin T Jordan
    Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Cancer Immunol Immunother 57:123-31. 2008
    ....
  73. ncbi Autophagy, the Trojan horse to combat glioblastomas
    Florence Lefranc
    Department of Neurosurgery, Erasme University Hospital, Belgium
    Neurosurg Focus 20:E7. 2006
    ..Thus, autophagy represents a kind of Trojan horse that can be used to bypass, at least partly, the dramatic resistance of glioblastoma to radiotherapy and proapoptotic-related chemotherapy...
  74. ncbi Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
    L A Hammond
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78829, USA
    J Clin Oncol 17:2604-13. 1999
    ....
  75. ncbi In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide
    Whoon Jong Kil
    Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:931-8. 2008
    ....
  76. ncbi Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
    V Chiarion Sileni
    Department of Medical Oncology, Padova Hospital, Azienda Ospedaliera, Italy
    Melanoma Res 11:189-96. 2001
    This randomized phase II trial was performed to define the activity and toxicity of the combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin (DDP) and tamoxifen (DBDT regimen) versus DTIC alone in patients with metastatic ..
  77. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients
    G Minniti
    Department of Radiotherapy Oncology, S Andrea Hospital, University La Sapienza, Via di Grottarossa 1035, Rome, Italy
    J Neurooncol 88:97-103. 2008
    ..We conducted a prospective trial in 32 consecutive elderly patients with glioblastoma who underwent surgery followed by radiotherapy (RT) plus concomitant and adjuvant temozolomide...
  78. ncbi PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo
    Jia Lu Jin
    Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Eur J Pharmacol 654:17-25. 2011
    PTD4-apoptin protein enters cells and harbors tumor-selective cell death activity. Dacarbazine is the mainstay of treatment for malignant melanoma...
  79. ncbi Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide
    Michael C Dobelbower
    The University of Alabama, Department of Radiation Oncology, Wallace Tumor Institute, Birmingham, Alabama, USA
    J Med Imaging Radiat Oncol 55:77-81. 2011
    ..To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide...
  80. ncbi Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway
    Yuan Yuan
    Department of Pharmacology, Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, China
    CNS Neurosci Ther 18:536-46. 2012
    ..The present study was to investigate the impact of resveratrol on the antitumor effects of temozolomide (TMZ), a standard treatment regiment of glioblastoma (GBM), in vitro and in vivo...
  81. ncbi Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma
    Christopher A Barker
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurooncol 109:391-7. 2012
    ..Survival of elderly patients with GBM may be prolonged with the use of concomitant TMZ during RT. An ongoing randomized study will determine the benefit of this approach in a prospective fashion...
  82. pmc Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine
    Sandeep Singh
    Drug Discovery Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Mol Cancer Ther 9:3330-41. 2010
    ..is an aggressive cancer with very low response rate against conventional chemotherapeutic agents such as dacarbazine (DTIC)...
  83. ncbi Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
    Jörg Felsberg
    Department of Neuropathology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Int J Cancer 129:659-70. 2011
    ..In conclusion, reduced expression of MMR proteins, but not changes in MGMT promoter methylation, is characteristic of glioblastomas recurring after the current standards of care...
  84. ncbi Clinical significance of molecular biomarkers in glioblastoma
    C Ang
    Department of Oncology, McGill University and the Segal Cancer Centre Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Can J Neurol Sci 37:625-30. 2010
    ..To review the impact of molecular biomarkers on response to therapy and survival in patients with primary glioblastoma (GBM)...
  85. ncbi Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution
    Philippe Metellus
    Service de Neurochirurgie, Hopital de la Timone, Marseille, France
    Ann Surg Oncol 18:2937-45. 2011
    ..To address this question we investigated the relationship between CD133 mRNA expression and patient outcome in a glioblastoma patient cohort...
  86. pmc Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC)
    M Nocera
    , Institute Gustave Roussy, Villejuif Cedex, 94805, France
    Br J Cancer 83:715-8. 2000
    Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations were observed...
  87. ncbi Glioblastoma survival in the United States before and during the temozolomide era
    Derek R Johnson
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Neurooncol 107:359-64. 2012
    ..However, median survival time after glioblastoma diagnosis in the SEER population remains well under one year, largely driven by poor prognosis in elderly patients...
  88. ncbi Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
    Ann I McCormack
    Cancer Genetics Unit, Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia
    Eur J Clin Invest 41:1133-48. 2011
    ..A DNA repair protein, 06-methylguanine-DNA methyltransferase (MGMT) has been suggested as a biomarker to predict response to temozolomide in pituitary tumours...
  89. ncbi Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents
    Shanbao Cai
    Section of Hematology Oncology, Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, 1044 West Walnut, R4 302C, Indianapolis, IN 46202, USA
    Cancer Res 65:3319-27. 2005
    ....
  90. ncbi DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells
    M Katayama
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, CA 94115 0875, USA
    Cell Death Differ 14:548-58. 2007
    ..These results show that DNA damaging agents induce an autophagy-associated ATP surge that protects cells and may contribute to drug resistance...
  91. ncbi Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma
    Hana Janouskova
    CNRS UMR 7213, Universite de Strasbourg, Faculte de Pharmacie, Illkirch, France
    Cancer Res 72:3463-70. 2012
    ..Direct activation of p53 may remain a therapeutic option in the subset of patients with high-grade gliomas that express both functional p53 and a high level of α5β1 integrin...
  92. pmc EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth
    Guillem Ramis
    Cancer Cell Biology Group, Institut Universitari d Investigacio en Ciencies de la Salut IUNICS, Universitat de les Illes Balears, Illes Balears, Spain
    PLoS ONE 7:e38770. 2012
    ..Interestingly, EGFR inhibition also perturbs Rho GTPase signaling and cellular morphology, leading to Rho/ROCK-dependent formation of actin stress fibres and the inhibition of glioma cell motility and invasion...
  93. ncbi Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study
    Sanjiv S Agarwala
    Division of Hematology Oncology, University of Pittsburgh Medical Center Pavilion, 5150 Centre Ave, Pittsburgh, PA 15232, USA
    J Clin Oncol 22:2101-7. 2004
    ..A multicenter, open-label, phase II study was conducted to assess the safety and efficacy of temozolomide in patients with brain metastases from metastatic melanoma (MM) who did not require immediate radiotherapy...
  94. ncbi Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications
    Y B Su
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:610-6. 2004
    ..4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine. Extended TMZ dosing regimens may be superior by delivering the drug continuously at a higher dose over time...
  95. pmc Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
    Claire Marie Elisabeth Sauvageot
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115
    Neuro Oncol 11:109-21. 2009
    ..Our results suggest that HSP90 inhibitors like 17-AAG may have therapeutic potential in GBM, either as a single agent or in combination with radiation...
  96. ncbi Inhibition of angiogenesis by non-toxic doses of temozolomide
    Hjalmar Kurzen
    Department of Dermatology, University of Heidelberg, Germany
    Anticancer Drugs 14:515-22. 2003
    ..Therefore, the antitumor activity of TMZ may, at least in part, be due to its antiangiogenic properties. The precise mechanism of its antiangiogenic action remains to be elucidated...
  97. pmc Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge
    Anindya Dasgupta
    Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine, Atlanta, GA 30322, USA
    Biochem Biophys Res Commun 391:170-5. 2010
    ..These results show that engineering immunocompetent cells to withstand chemotherapy challenges can enhance tumor cell killing when chemotherapy is applied in conjunction with cell-based immunotherapy...
  98. ncbi Temozolomide for corticotroph pituitary adenomas refractory to standard therapy
    Troy H Dillard
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Pituitary 14:80-91. 2011
    ..To our knowledge, this case represents the most rapid robust CA shrinkage response reported to date. Further randomized clinical trials of TMZ in the treatment of aggressive pituitary adenomas are warranted...
  99. ncbi Temozolomide: a novel treatment for pituitary carcinoma
    Stephen Lim
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Lancet Oncol 7:518-20. 2006
  100. ncbi Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases
    Marco Losa
    Pituitary Unit, Department of Neurosurgery, Istituto Scientifico San Raffaele, Universita Vita Salute, Via Olgettina 60, 20132 Milano, Italy
    Eur J Endocrinol 163:843-51. 2010
    ..We assessed the efficacy of treatment with temozolomide, an oral second-generation alkylating agent, in a consecutive series of six patients with aggressive pituitary adenomas...
  101. ncbi A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients
    M Schaich
    Department of Medicine I, University Hospital C G Carus, Dresden, Germany
    Ann Oncol 20:175-81. 2009
    ....

Research Grants62

  1. Spontaneous activity in the developing cochlea
    Dwight E Bergles; Fiscal Year: 2010
    ..Furthermore, these studies may reveal one mechanism by which activity can be induced in afferent nerves in the absence of sound, which may have direct relevance to human conditions such as tinnitus. ..
  2. Systemic Application for Injury Site Specific Delivery via Neutrophils to Treat B
    XUDONG J LI; Fiscal Year: 2013
    ..This method is much more cost- effectiveness compared to epidural steroid injection. ..
  3. Listeria-Based Therapeutic Cancer Vaccine for Melanoma
    Dirk G Brockstedt; Fiscal Year: 2011
    ..The overall goal of this proposal is to develop a therapeutic vaccine for melanoma that is based on inactivated strains of recombinant Listeria monocytogenes expressing melanoma-associated antigens. ..
  4. QUANTITATIVE ANALYSIS OF AGING RETINA
    Christine A Curcio; Fiscal Year: 2012
    ....
  5. Mechanics of Inner Ear Hair Bundles
    KIRIAKI DOMENICA KARAVITAKI; Fiscal Year: 2012
    ..Mutation of similar links is known to cause inherited deafness in mice and humans, and this sort of sliding adhesion represents a new type of mechanism in cell biology. ..
  6. Superantigen-Induced Vascular Injury and DIC
    JACK J HAWIGER; Fiscal Year: 2011
    ..abstract_text> ..
  7. Molecular Basis for Priming of the Neutrophil NADPH Oxidase in Trauma and Sepsis
    ALBERT T HSU; Fiscal Year: 2010
    ..In regards to public health, the overall goal of this research project is to reduce morbidity and mortality from MOSF in Surgical Intensive Care Units. ..
  8. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma
    Barry Jones; Fiscal Year: 2013
    ..Surgery and radiation therapy are the mainstay of treatment. Dacarbazine-based chemotherapy remains after 30 years, for want of anything better, to be the main systemic therapy...
  9. Rapid Label-Free Detection of Acute Promyelocytic Leukemia
    Lydia L Sohn; Fiscal Year: 2012
    ..Senior Personnel, George Anwar, Ph.D. at UC Berkeley will lead in the software and hardware design and packaging of the device for point-of-care. ..
  10. Invasion of glioblastoma multiforme (GBM) cells in organotypic brain slices
    ZEV ARI BINDER; Fiscal Year: 2013
    ....
  11. Therapeutic factor XI blockade for sepsis
    ERIK IAN contact TUCKER; Fiscal Year: 2010
    ..We address this major medical need with a new antithrombotic antibody product candidate to provide a safe and effective alternative to APC. ..
  12. Load-mediated Adaptation of the Bone-PDL-Tooth Complex in Vertebrates
    Sunita P Ho; Fiscal Year: 2013
    ..Such adapted sites could act as the local stress points inducing positive feedback when the complex is subjected to implants and/or periodontitis, normal or therapeutic loads (orthodontic braces) subsequently impairing function. ..
  13. MULTIPHOTON CONFOCAL MICROSCOPE
    Liza A Pon; Fiscal Year: 2010
    ..As a compo- nent of our Confocal and Specialized Microscopy Facility, the instrument will be accessible to Major Users and others throughout the University, promoting collaboration and exchange of ideas. ..
  14. In-Incubator Live Cell Fluorescence/DIC Time Lapse Imaging System
    Martin F Schneider; Fiscal Year: 2010
    ..Instrument maintenance is supported by the School of Medicine, the Department of Biochemistry and Molecular Biology, and users fees. ..
  15. Activity-dependent modulation of the Drosophila mushroom body function by FMRP
    JONATHAN STAPLES; Fiscal Year: 2012
    ..This research proposal utilizes the powerful Drosophila genetic system to define the functional requirements of FMRP in the mushroom body learning and memory center. ..
  16. Therapeutic factor XI blockade for sepsis
    ERIK IAN TUCKER; Fiscal Year: 2013
    ..Determine the toxicity of humanized AXIMAB in preclinical studies. Success of this Phase II project will support the advancement of AXIMAB into clinical studies. ..
  17. Intravital Multiphoton Microscope
    Florea Lupu; Fiscal Year: 2010
    ..A partial list of human disease studies at the OMRF that will benefit from this technology include cardiovascular and thrombotic disorders, inflammation and autoimmunity, cancer, neurodegenerative diseases and bacterial infections. ..
  18. Cardiac Repair and Regeneration in Doxorubicin-induced Cardiomyopathy
    Dinender Kumar Singla; Fiscal Year: 2012
    ..Moreover, the use of TCC-ES cells or ES-CM that release various factors that stimulate tissue repair and regeneration may have promise as a new therapeutic strategy in the field of regenerative medicine. ..
  19. Orientation independent DIC and polarization microscopy
    Michael Shribak; Fiscal Year: 2011
    ....
  20. Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma
    Wei Li; Fiscal Year: 2013
    ..Despite decades of extensive research, dacarbazine (DTIC) remains the gold standard for treating malignant melanoma, yet it provides complete remission in fewer ..
  21. Modulation by ethanol of astrocyte-mediated hippocampal synaptogenesis
    Pamela J Roqué; Fiscal Year: 2012
    ..This study has implications for the cognitive dysfunction found in children with Fetal Alcohol Spectrum Disorder (FASD). Increased understanding in this area could lead to potential treatments for children exposed in utero to ethanol. ..
  22. Microscope for Microstructural Characterization of Orthopaedic Tissues
    Dawn M Elliott; Fiscal Year: 2010
    ....
  23. Regulation of the Vasculature by Invading Glioma Cells
    STACEY MICHELLE WATKINS; Fiscal Year: 2013
    ..Data obtained from this proposal will aid in the understanding of an aspect glioma biology that may provide specific molecular targets for future anti-invasive therapy. ..
  24. MOLECULAR MECHANISMS OF SEPTIC SHOCK
    JACK HAWIGER; Fiscal Year: 2003
    ..The ultimate goal of the proposed studies is to provide a new conceptual framework for reduction of high mortality due to septic shock. ..
  25. Family-based transition program for school-aged children with Sickle Cell Disease
    Lamia P Barakat; Fiscal Year: 2011
    ..abstract_text> ..
  26. HEPARIN INDUCED THROMBOCYTOPENIA/THROMBOSIS
    GIAN VISENTIN; Fiscal Year: 2000
    ..Numerous conferences and seminars are held throughout the year at the BRI and the nearby Medical College of Wisconsin. This environment should be ideal for the candidate's development as an investigator. ..
  27. Serous Cell Secretion and Cystic Fibrosis Lung Disease
    Jeffrey J Wine; Fiscal Year: 2010
    ..Successful completion of these aims will clarify the contribution of glands, which produce approximately 95% of airway mucus, to the mucus clearance and chemical shield components of airway innate defenses. ..
  28. Orientation independent DIC and polarization microscopy
    Michael Shribak; Fiscal Year: 2013
    ..The polychromatic polscope will be able to provide sharp images of fast moving birefringent organelles, rapid birefringence propagation caused be nerve impulses, etc. ..
  29. Vibrio Cholerae Colonization of Chitin Surfaces
    Gary Schoolnik; Fiscal Year: 2007
    ..If successful, this project should generate new information about the persistence and control of infectious agents in aquatic reservoirs. ..
  30. Nikon A1 Confocal Microscope
    Jeffrey Robbins; Fiscal Year: 2010
    ..The instrumentation will be operated and maintained by the PI and a Ph.D.-level facility staff scientist. Together these personnel have over 45 years of imaging experience, ensuring that the services will be provided in a timely manner. ..
  31. ASSESSMENT OF GENETIC DAMAGE INDUCED BY CHEMOTHERAPY
    JAN LIANG; Fiscal Year: 1992
    ..nitrogen, mustard, vincristine, procarbazine and prednisone (MOPP) and adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)...
  32. REPAIR OF HAIR BUNDLES IN SEA ANEMONES
    GLEN WATSON; Fiscal Year: 1999
    ..Long range plans for this project including testing the usefulness of anemone repair proteins as possible therapeutic agents for damaged hair bundles in vertebrates. ..
  33. ZEISS Spinning Disc/LSM700 Point Scanning Confocal Microscope with Incubation Sys
    CRISTINA MARIA FERNANDEZ VALLE; Fiscal Year: 2010
    ..This will help the unit fulfill its strategic goal defined in 2003 to recruit 34 new faculty to build a well-funded nationally recognized biomedical research program at UCF. ..
  34. Request for live cell confocal microscope for BSL3 facility
    Simon C Watkins; Fiscal Year: 2010
    ..The device requested here is a critical component of the continued growth of this institutional facility, such that it can serve the needs of researchers who want to integrate live cell imaging of pathogens into their research. ..
  35. Using VA registry data to estimate age-related risk trajectories for HIV patients
    Song Zhang; Fiscal Year: 2013
    ..The webpages is constructed to help clinicians utilize the knowledge about CVD risk in HIV patients learned from CCR data. ..
  36. Endogenous GABAergic Activity
    Istvan Mody; Fiscal Year: 2007
    ....
  37. Deltavision RT Image Restoration System for Established Research Core Facility
    Thomas Keller; Fiscal Year: 2007
    ..meningitides. [unreadable] [unreadable] [unreadable]..
  38. Novel anti-melanoma agents and their mechanism of action
    Harish Joshi; Fiscal Year: 2009
    ..Malignant melanoma is considered a chemotherapy refractory tumor. Currently dacarbazine is the single most active agent against melanoma but has a low response rate of approximately 20%...
  39. Quantitative Optical Phase, Amplitude, and Polarization Microscopy
    Remy Tumbar; Fiscal Year: 2010
    ....
  40. PLATELET-ENDOTHELIAL DYSFUNCTION BY FIBRINOGEN PEPTIDE
    Charles Chen; Fiscal Year: 1992
    ..A key research interest of hers is fibrinogen and FDPs/fdps. The sponsor and the environment in the Longwood Medical Area should be a fertile ground for Dr. Chen to develop into an independent investigator...
  41. PLATELET REACTIVITY & DISORDERS OF PLATELET FUNCTION
    Harvey Weiss; Fiscal Year: 1980
    ....
  42. INHIBITORS OF THE EXTRINSIC BLOOD COAGULATION PATHWAY
    TERENCE BRUNCK; Fiscal Year: 1991
    ..Molecular modeling and peptidomimetic techniques will be used to design active, stable inhibitors of the extrinsic coagulation pathway and, hence, DIC...
  43. INTRAVITAL VIDEO-RATE CONFOCAL MICROSCOPE
    Bruce Furie; Fiscal Year: 2001
    ..The BioRad RTS2000 real-time laser confocal system, fitted to a Nikon E600FN microscope, will provide a group of investigators with instrumentation to significantly advance their fields. ..
  44. Mechanisms/GHB/models/acute/chronic GBH intoxication.
    Istvan Mody; Fiscal Year: 2005
    ..abstract_text> ..
  45. REGULATORY ROLES OF LACTOFERRIN IN HEMOSTASIS
    Haifeng Wu; Fiscal Year: 2003
    ....
  46. MORPHOLOGY-BASED RATING OF EGG DEVELOPMENT POTENTIAL
    Clifford Hoyt; Fiscal Year: 2000
    ..We would also expect interest from veterinarian clinics. ..
  47. LASER SCANNING CONFOCAL MICROSCOPE
    Jianjie Ma; Fiscal Year: 2003
    ..abstract_text> ..
  48. Better, Faster Live-Cell Imaging: Motion-Enhanced DIC (MEDIC) with Fluorescence
    Jed Macosko; Fiscal Year: 2009
    ....
  49. Differential Interference Contrast Optofluidic Microscopy
    Changhuei Yang; Fiscal Year: 2009
    ....
  50. CONFOCAL LASER SCAN MICROSOCPE
    Robert Goldman; Fiscal Year: 1990
    ..The LSM is a relatively new research tool which will revolutionize many areas of structural biology, especially those dealing with subcellular structure and function...
  51. FUNCTIONAL MODEL FOR MITOSIS IN CELL LINES
    W Cande; Fiscal Year: 1999
    ..An improved understanding of mitosis should eventually lead to new approaches to cancer chemotherapy and to control of abnormal chromosome segregation. ..
  52. Acrylamide and Diketone Neurotoxicity: Axonal transport
    DALE SICKLES; Fiscal Year: 2005
    ..These studies will enhance the evaluation of the emerging concept of motor protein defects producing specific peripheral neuropathies. ..
  53. CYTOPLASMIC MOTILITY IN EARLY DEVELOPMENT
    WILLIAM SAXTON; Fiscal Year: 2002
    ..5) To uncover functions for redundant embryonic motors by multiple motor knock-outs. Multiple knock-outs are straightforward with the RNAi approach. ..
  54. CYTOSKELETAL DEFECTS IN LIVING GLAUCOMA TRABECULAR CELLS
    EDWARD O BRIEN; Fiscal Year: 1999
    ....
  55. Therapy of Melanoma with Bortezomib and Interferon-alpha
    William Carson; Fiscal Year: 2007
    ..The current standard of care for metastatic disease is single-agent dacarbazine which has an overall response rate of just 15%...
  56. UPDATE IMAGING CORE FACILITY
    Katherine Luby Phelps; Fiscal Year: 1992
    ..It is hoped that with these additions the Imaging Core Facility will become a state-of-the-art facility for biomedical research and will better meet the needs of the major users...
  57. MULTIPHOTON CONFOCAL MICROSCOPE
    John Lemasters; Fiscal Year: 2000
    ..Multiphoton microscopy will substantially extend our successful and highly productive efforts applying digitized optical microscopy to problems of biology and medicine. ..
  58. DIGITAL IMAGING FLUORESCENCE MICROSCOPY FACILITY
    Kevin Strange; Fiscal Year: 1991
    ....
  59. Dendritic Role in Dopamine Neuron Firing
    Joseph Callaway; Fiscal Year: 2004
    ..abstract_text> ..
  60. AUTOMATED VIDEO MICROFLUOROMETRY AND INJECTION SYSTEM
    Claude Lechene; Fiscal Year: 1991
    ..Scheduling, new users, maintenance and future use will be reviewed by a local advisory committee...
  61. PATHOGENESIS OF FIBRINOGEN ALTERATIONS ON SEPSIS
    JUSTINE CARR; Fiscal Year: 1990
    ..Other evaluations will be dictated by observations made in Phase I. After careful delination of the structural and functional alterations of fibrinogen occurring in sepsis, a more rational basis for design of therapy can evolve...
  62. STEROIDS STIMULATE AXON REGENERATION IN THE ADULT BRAIN
    Thomas Kuhn; Fiscal Year: 2001
    ..Understanding the principal of testosterone- dependent axon outgrowth in the presence of myelin could improve our knowledge to address functional regeneration in the adult mammalian CNS. ..